Building Competency in Diabetes Education THE ESSENTIALS

TREATMENT MODALITIES: PHARMACOLOGICAL THERAPIES | 6-41

• Causal association with lower limb amputation remains uncertain. Assess risk for amputation prior to initiation and counsel on importance of routine preventative foot care and adequate hydration. Caution • With diuretics, especially loop diuretics, due to the increased risk of adverse events of volume depletion Contraindications • eGFR less than 45 mL/min/1.73m 2 • Severe renal impairment, end-stage renal disease or on dialysis.

• TDD: 5 mg - 15 mg • Frequency: QD in the

morning, with or without food.

Dosing schedule • Initiate 5 mg once daily. • Titrate dose to 15 mg once daily, if additional glycemic control is needed. • Available: 5 mg, 15 mg Dose that has demonstrated cardiorenal benefits: • ertugliflozin has demonstrated CV safety, but not CV benefit

Combination Products Canagliflozin/metformin (Invokamet ® ) available in 50 mg/500 mg, 50 mg/1,000 mg, 150 mg/500mg, 150 mg/1,000 mg Dapagliflozin/metformin (Xigduo ® ) available in 5 mg/850 mg, 5 mg/1,000 mg Empagliflozin/metformin (Synjardy™) available in 5 mg/500 mg, 5 mg/850 mg, 5 mg/1,000 mg, 12.5 mg/500 mg, 12.5 mg /850 mg, 12.5 mg/1000 mg Ertugliflozin/metformin (Segluromet ® ) available in 2.5 mg/500 mg, 2.5 mg/1,000 mg, 7.5 mg/500mg, 7.5 mg/1,000 mg Other Combinations:

Empagliflozin/ linagliptin (Glyxambi®) available in 10 mg/5mg; 25 mg/5 mg Sitagliptin/ertugliflozin (Steglujan®) available in 100 mg/5 mg, 100 mg/15 mg